

Dear

FREEDOM OF INFORMATION – PRESCRIBING

I write in response to your request for information in relation to prescribing within NHS Lothian

Attached is the completed word document for request, however, patient issues are largely unidentifiable, therefore we have also included below the total dose units issued (where dose unit defined as one single unit i.e. injection).

Question:

1. How many patients were treated **in total, regardless of diagnosis**, with the following medicines in the 3 months between the start of October 2023 and end of December 2023?

Answer:

October 2023 - December 2023	
Medication	Units Issued (single injection)
Benralizumab	156
Dupilumab	1101
Mepolizumab	453
Omalizumab	797
Reslizumab	0
Tezepelumab	6

Question:

2. How many patients were treated for **severe asthma**, atopic dermatitis, CRwNP and other indications with the following medicines in the 3 months between the start of October 2023 and end of December 2023?

Answer:

Name of medicine	Severe asthma (please include all types or references to asthma)
2.1 Benralizumab (Fasenra)	80
2.2 Dupilumab (Dupixent)	21

2.3 Mepolizumab (Nucala)	133
2.4 Omalizumab (Xolair)	54
2.5 Reslizumab (Cinqaero)	0
2.6 Tezepelumab (Tezspire)	5<

Question:

3. How many patients were treated **by department** in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2023 and end of December 2023?

Answer:

October 2023 - December 2023			
Medication	Respiratory	Dermatology	Other
Benralizumab	126	0	30
Dupilumab	126	963	12
Mepolizumab	412	0	41
Omalizumab	527	234	36
Reslizumab	0	0	0
Tezepelumab	5<	0	5<

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the tables above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhsllothian.scot/FOI/Pages/default.aspx>

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing, Midwifery and AHPs
Cc: Chief Executive
Enc.

Q1. How many patients were treated **in total, regardless of diagnosis**, with the following medicines in the 3 months between the start of October 2023 and end of December 2023?

Name of medicine	Number patients treated
1.1 Benralizumab (Fasenra)	Information Unavailable
1.2 Dupilumab (Dupixent)	174
1.3 Mepolizumab (Nucala)	Information Unavailable
1.4 Omalizumab (Xolair)	Information Unavailable
1.5 Reslizumab (Cinqaero)	Information Unavailable
1.6 Tezepelumab (Tezspire)	Information Unavailable

Q2. How many patients were treated for **severe asthma**, atopic dermatitis, CRwNP and other indications with the following medicines in the 3 months between the start of October 2023 and end of December 2023?

Name of medicine	Severe asthma (please include all types or references to asthma)	Chronic rhinosinusitis with nasal polyps (CRwNP)	Atopic Dermatitis	Other
2.1 Benralizumab (Fasenra)		N/A	N/A	N/A
2.2 Dupilumab (Dupixent)				
2.3 Mepolizumab (Nucala)			N/A	
2.4 Omalizumab (Xolair)			N/A	
2.5 Reslizumab (Cinqaero)		N/A	N/A	N/A
2.6 Tezepelumab (Tezspire)		N/A	N/A	N/A

Q3. How many patients were treated **by department** in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2023 and end of December 2023?

Name of medicine	Respiratory departments	Dermatology departments	Other
3.1 Benralizumab (Fasenra)	Information Unavailable	0	Information Unavailable
3.2 Dupilumab (Dupixent)	Information Unavailable	153	Information Unavailable
3.3 Mepolizumab (Nucala)	Information Unavailable	0	Information Unavailable
3.4 Omalizumab (Xolair)	Information Unavailable	45	Information Unavailable
3.5 Reslizumab (Cinqaero)	Information Unavailable	0	Information Unavailable
3.6 Tezepelumab (Tezspire)	Information Unavailable	0	Information Unavailable